Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Artiva Biotherapeutics (ARTV) over the last 3 years, with Sep 2025 value amounting to $24.5 million.

  • Artiva Biotherapeutics' Shares Outstanding (Diluted Average) rose 29.55% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 29.55%. This contributed to the annual value of $11.3 million for FY2024, which is 1302.54% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Shares Outstanding (Diluted Average) of $24.5 million as of Q3 2025, which was up 0.42% from $24.4 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Shares Outstanding (Diluted Average) registered a high of $24.5 million during Q3 2025, and its lowest value of $800,889 during Q2 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $9.1 million (2023), whereas its average is $11.4 million.
  • Data for Artiva Biotherapeutics' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 2,906.08% (in 2025) over the last 5 years.
  • Over the past 3 years, Artiva Biotherapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $802,747 in 2023, then soared by 1,302.54% to $11.3 million in 2024, then increased by 29.55% to $24.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $24.5 million in Q3 2025, compared to $24.4 million in Q2 2025 and $24.3 million in Q1 2025.